Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 9Gynecologic 2Genitourinary 2NET 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Vipoma 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Gastrinoma 1Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 5Sunitinib 4lutetium Lu 177 dotatate 2PM 01183 2Octreotide 2Doxorubicin 2trifluridine tipiracil drug combination 1telotristat ethyl 1repotrectinib 1pralsetinib 1pegfilgrastim 1pasireotide 1motesanib diphosphate 1epothilone B 1dactolisib 1copper dotatate CU-64 1batifiban 1avelumab 1alectinib 1Temozolomide 1TKM-080301 1Surveys and Questionnaires 1SNX-5422 1Referral and Consultation 1Radiomics 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × epothilone B × NET × Clear all
NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Novartis

Phase 2 Completed
33 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡